Shaygannejad et al. Seizure characteristics in multiple sclerosis patients. J Res Med Sci. 2013 Mar;18(Suppl 1):S74-7
BACKGROUND: To evaluate seizure characteristic among MSers with coexistent seizure activity compared to control group.
MATERIALS AND METHODS: This study is a cross-sectional study which was conducted by reviewing the clinical records of MSers with a definite diagnosis of MS according to McDonald’s criteria from March 2007 to June 2011, who referred to the MS clinic of the university.
RESULTS: A total of 920 MSers with a diagnosis of MS were identified, among whom 29 MSers (3.15%) with seizure activity (case) due to MS with the mean age of 32.6 ± 6.23 years were analyzed. Also, fifty MS MSers without any seizure occurrence with the mean age of 33.7 ± 7.4 years were used as our control group. In the case group, seizures were generally tonic-clonic in 23 MSers (79.3%), complex partial in four (13.8%), and simple partial in two (5.9%). The 26 available interictal EEGs in MSers showed abnormal EEG pattern in 22 (84.6%) of them, including focal epileptic form discharge or focal slowing in 10 (38.5%), generalized discharge (spike-wave, polyspike, or general paroxysmal fast activity) in 10 (38.5%), and general slowing activity in 10 record (38.5%). MRI reviews of the 26 available brain MRIs showed subcortical white mater lesions in 22 (84.6%) of MSers with seizure. All MRIs were performed within one month after the first seizure episode. Amongst 48 available MRIs in our control group, 91.7% (44 cases) showed periventricular lesions and in 8.3% (4 cases) subcortical white matter lesions were reported.
CONCLUSION: The result of this study demonstrated the higher rate of subcortical white matter lesion in MSers with seizure occurrence compared to control group.
Multiple Sclerosis Research: Sudden death in MS or SUDMUS (1)
08 Feb 2012
“Sudden death is very topical in view of the recent death of a patient on Fingolimod and the European Medicine Agency’s decision to review the safety of the drug. I would be very interested to know if the unfortunate MS’er who …
http://multiple-sclerosis-research.blogspot.com/
Other posts on seizures:
FDA warns about seizures with MS drug Ampyra or Fampridine
27 Jul 2012
The U.S. Food and Drug Administration (FDA) on Monday said MSers who take the drug Ampyra (known as Fampridine in Europe), have a higher risk of seizures when starting the treatment. The FDA also updated the label for …
http://multiple-sclerosis-research.blogspot.com/
Multiple Sclerosis Research: Research: Seizures in MS
20 May 2012
“Seizures are not uncommon in MSers and are presumably due to gray matter involvement. The most common are secondary generalised epilepsy; these start with an aura before spreading to the whole brain. Seizures in …
http://multiple-sclerosis-research.blogspot.com/
Multiple Sclerosis Research: Symptoms in MS: tremors, seizures …
22 Jul 2011
Re: “The fewer medicines you take, the better off you’ll be.” No not really; it is always a trade off between symptoms and their impact on your functioning (activities of daily living, social and occupational) and how effective they …
http://multiple-sclerosis-research.blogspot.com/
Multiple Sclerosis Research: Research: MS brain lesions and epilepsy
16 Jan 2013
OBJECTIVES: Previous studies have reported an increased risk for epileptic seizures in MSers. However, data on the pathogenesis of seizures remain inconclusive. The aim of this study is to evaluate prevalence, clinical and …
http://multiple-sclerosis-research.blogspot.com/
